Agendia Responds to “Clinical Insights on MINDACT”
Dear Dr. Febbo, I recently received an email from Read More
Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.
PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Read More
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
PUBLICATION: N Engl J Med 2016; 375:717-729; DOI: 10.1056/NEJMoa1602253. AUTHORS: Read More
New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy
46% of patients identified as high risk for recurrence according Read More
MINDACT Supplementary Appendix NEJM 2016
SUPPLEMENTARY APPENDIX: This appendix has been provided by the authors Read More
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures
PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Read More
Breast Cancer: Determining the Genetic Profile from Ultrasound-Guided Percutaneous Biopsy Specimens Obtained During Diagnostic Workups
PUBLICATION: Radiología (English Edition) Volume 58, Issue 3, May–June 2016, Read More
New Data Shows Agendia’s MammaPrint can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
The PRospective study Of MammaPrint in breast cancer patients with Read More
Cáncer de Mama: Determinación del Perfil Genético a Partir de la Biopsia Percutánea Ecoguiada Diagnóstica
PUBLICATION: Radiología; Vol. 58. Issue 3. pages 214-220 (May-June 2016) Read More
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to their Medical Advisory Board
Company also announces new ASCO data presentation from the prospective Read More
